Genmab — Juli 2023
-
High-Growth Biopharma: Thriving Through Change & Volatility
To navigate growth, biopharma companies must empower leaders, maintain an agile culture that prioritizes the patient, and invest in R&D.
(www.russellreynolds.com)
-
-
J&J forventer at behandle 3/4 af alle MM pts inden udgangen af dette tiår. De føler sig bedre rustet til IRA end andre firmaer (hexa-cd38?). De nævnte også noget om at de altid var på jagt efter muligheder der kunne skabe mere værdi for et asset i deres hånd, end de havde pt.
-
J&J again boosts full-year outlook as Darzalex https://firstwordpharma.com/story/5762723
-
J&J's Darzalex stays on its upward trajectory as company adds $1B to annual sales projection https://www.fiercepharma.com/pharma/johnson-johnsons-darzalex-continues-its-upward-trajectory-company-boosts-2023-revenue
-
Ved ikke om denne har været nævnt"Genmab (+1,9%, 2769) har fået hævet kursmålet for sin ADR-notering i USA til 45 dollar fra 43 dollar af BMO Capital, der fastholder den neutrale anbefaling "market perform". Torsdag lukkede ADR-noteringen i kurs 41,45 dollar efter en stigning på 1,3 pct. Der går ti ADR-aktier på én dansk. "
-
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY
) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) https://ir.genmab.com/news-releases/news-release-details/genmab-announces-abbvie-receives-positive-chmp-opinion -
Har administrator slettet i dagens chat?
-
Næ..Hvorfor det?
-
Syns blot jeg læste to indlæg om udtalelse fra CHMP, men jeg skal måske forbi Louis Nielsen. Tak
-
Ok. Det var mit eget som var magen til det fra E L . Derfor blev det slettet.
-
Vi postede i samme sekund. Opdagede først fejlen lidt senere.
-
Det kan næppe være en fejl
-
Janssen Receives Positive CHMP Opinions for Novel Bispecific Antibodies TALVEY
▼ (talquetamab) and TECVAYLI▼ https://www.jnj.com/janssen-receives-positive-chmp-opinions-for-novel-bispecific-antibodies-talvey-talquetamab-and-tecvayli-teclistamab-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind